| Title | HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. |
| Publication Type | Journal Article |
| Year of Publication | 2009 |
| Authors | Paltiel, David A., Kenneth A. Freedberg, Callie A. Scott, Bruce R. Schackman, Elena Losina, Bingxia Wang, George R. Seage, Caroline E. Sloan, Paul E. Sax, and Rochelle P. Walensky |
| Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
| Volume | 48 |
| Issue | 6 |
| Pagination | 806-15 |
| Date Published | 2009 Mar 15 |
| ISSN | 1537-6591 |
| Keywords | Adenine, Adult, Anti-HIV Agents, Chemoprevention, Computer Simulation, Cost-Benefit Analysis, Deoxycytidine, HIV Infections, Homosexuality, Humans, Male, Phosphonic Acids, Risk Assessment, United States |
| Abstract | The combination of tenofovir and emtricitabine shows promise as HIV preexposure prophylaxis (PrEP). We sought to forecast clinical, epidemiologic, and economic outcomes of PrEP, taking into account uncertainties regarding efficacy, the risks of developing drug resistance and toxicity, behavioral disinhibition, and drug costs. |
| DOI | 10.1086/597095 |
| Alternate Journal | Clin. Infect. Dis. |
